ERBB2 and neoplasm: Although the in vivo administration of Her2-AAV-PD-1 had only marginal anti-tumor activity and combination with cytostatic chemotherapy led to only modest improvement in tumor growth suppression [98], this targeted delivery method can be improved on for increased efficacy and decreased toxicities.